object
assess
valu
pct
rapid
sensit
marker
diagnosi
prognosi
therapi
lower
respiratori
tract
bacteri
infect
necessit
antimicrobi
treatment
compar
marker
marker
infect
includ
creactiv
protein
crp
total
whiteblood
cell
count
wbc
patient
method
sixti
patient
enrol
studi
subject
complet
histori
take
physic
examin
laboratori
investig
includ
complet
blood
count
blood
gase
blood
chemistri
bacteriolog
cultur
sputum
blood
serolog
atyp
pcr
respiratori
virus
serum
creactiv
protein
crp
pct
level
measur
patient
divid
two
group
group
includ
patient
cultur
neg
bacteri
infect
group
includ
patient
cultur
posit
group
patient
given
antibiot
therapi
accord
cultur
sensit
result
result
reveal
signific
differ
group
group
patient
regard
age
sex
clinic
manifest
final
diagnosi
white
blood
cell
count
blood
gase
number
admit
patient
intens
care
unit
admiss
length
hospit
stay
signific
increas
pct
crp
level
detect
group
compar
group
initi
open
access
cc
byncnd
licens
diagnosi
cutoff
valu
ngml
pct
gave
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
diagnost
effici
diagnosi
respiratori
tract
bacteri
infect
howev
cutoff
valu
mgl
crp
gave
sensit
specif
ppv
npv
diagnost
effici
antibiot
therapi
pct
crp
level
drop
group
patient
compar
pretreat
level
conclus
serum
pct
level
could
use
novel
marker
lower
respiratori
tract
bacteri
infect
diagnosi
prognosi
follow
therapi
reduc
sideeffect
unnecessari
antibiot
use
lower
cost
longterm
lead
diminish
drug
resist
acut
respiratori
infect
ari
compris
larg
heterogen
group
infect
includ
bacteri
infect
viral
infect
infect
etiolog
earli
initi
adequ
antibiot
therapi
cornerston
treatment
bacteri
ari
associ
improv
clinic
outcom
howev
overus
antibiot
overprescript
outpati
prolong
durat
antibiot
therapi
patient
bacteri
ari
hospit
intens
care
set
associ
increas
resist
common
bacteria
high
cost
advers
drug
reaction
novel
approach
estim
likelihood
bacteri
infect
sever
diseas
use
blood
biomark
mirror
host
respons
infect
sever
infect
recent
year
procalcitonin
pct
emerg
promis
marker
diagnosi
bacteri
infect
higher
level
found
sever
bacteri
infect
viral
infect
nonspecif
inflammatori
diseas
henc
pct
may
use
support
clinic
decis
make
initi
discontinu
antibiot
therapi
procalcitonin
prohormon
calcium
homeostasi
hormon
calcitonin
noninfecti
condit
produc
neuroendocrin
medullari
ccell
thyroid
gland
normal
subject
circul
procalcitonin
concentr
low
ngml
bacteri
infect
select
induc
increas
concentr
procalcitonin
parenchym
tissu
endotoxin
lipopolysaccharid
bacteri
cell
wall
host
respons
infect
stimul
product
procalcitonin
cytokin
b
tumor
necrosi
factora
upregul
pct
correl
sever
extent
bacteri
infect
result
accumul
procalcitonin
unlik
neuroendocrin
cell
parenchym
cell
lack
abil
cleav
procalcitonin
matur
form
calcitonin
convers
interferonc
cytokin
releas
respons
viral
infect
block
upregul
pct
result
higher
specif
pct
toward
bacteri
infect
quantit
pct
may
help
distinguish
sever
bacteri
infect
milder
viral
ill
detect
within
h
peak
within
h
oppos
crp
begin
rise
h
peak
h
pct
product
impair
neutropenia
immunosuppress
state
pct
level
parallel
sever
inflammatori
insult
infect
mean
sever
diseas
higher
level
furthermor
procalcitonin
util
prognost
indic
higher
serum
concentr
relat
risk
mortal
pct
advantag
biomark
common
clinic
use
creactiv
protein
crp
white
blood
cell
count
advantag
includ
specif
bacteri
infect
rapid
rise
insult
h
rapid
declin
immun
control
infect
halflif
h
excel
correl
sever
ill
higher
level
sever
ill
lack
impact
antiinflammatori
immunosuppress
state
product
pct
use
guid
follow
situat
differenti
bacteri
vers
viral
respiratori
tract
infect
determin
durat
antibiot
treatment
respiratori
infect
diagnosi
monitor
sepsi
septic
shock
prognost
use
classifi
patient
low
risk
high
risk
bacteri
infect
andor
sepsi
predict
mortal
monitor
respons
antibacteri
therapi
differenti
bacteri
vers
viral
mening
diagnosi
bacteri
infect
neutropen
patient
decis
regard
antimicrobi
therapi
base
sole
procalcitonin
serum
concentr
procalcitonin
place
clinic
context
patient
scenario
consid
site
possibl
infect
likelihood
bacteri
infect
sever
ill
studi
sepsi
evalu
use
pct
initi
discontinu
antibiot
decis
initi
therapi
icu
driven
sever
ill
clinic
assess
likelihood
infect
pct
use
guid
assist
initi
stop
antibiot
pct
level
declin
increas
strong
prognost
indic
lack
control
infect
host
immun
system
andor
antibiot
recommend
diagnost
proceduresimag
broader
spectrum
antibiot
initi
base
upon
rise
valu
recent
studi
use
pct
valu
lgl
alert
suggest
broaden
therapi
imag
high
valu
also
give
prognosi
increas
length
stay
icu
ventil
situat
recommend
care
reassess
patient
sitessourc
infect
evid
resist
pathogen
decis
regard
intervent
made
base
upon
evalu
aim
review
focus
respiratori
infect
give
potenti
use
pct
guid
diagnos
bacteri
infect
differenti
bacteri
viral
diseas
prognost
sever
patient
condit
guid
clinic
decis
initi
antibiot
therapi
safe
discontinu
total
number
patient
male
femal
includ
studi
decemb
januari
randomli
select
outpati
clinic
inpati
depart
al
sabah
hospit
kuwait
patient
present
fever
cough
expector
dyspnea
suspect
lower
respiratori
tract
infect
main
diagnosi
includ
pneumonia
acut
exacerb
asthma
copd
acut
bronchiti
includ
patient
subject
follow
detail
histori
physic
examin
chest
radiographi
done
patient
sputum
blood
collect
bacteri
cultur
use
specif
media
organ
microorgan
record
detect
sputum
blood
cultur
fresh
heparin
arteri
blood
sampl
collect
blood
gase
analysi
room
air
avlautoanlyzerroch
serolog
atyp
includ
chlamydia
pneumonia
igaigmigg
coxiella
bruntii
igmigg
legionella
pneumonia
igmigg
mycoplasma
pneumonia
iga
igmigg
use
enzym
link
immunosorb
assay
elisa
immunoassay
suit
determin
antibodi
field
infecti
serolog
reaction
base
specif
interact
antibodi
correspond
antigen
therefor
test
strip
serion
elisa
classic
microtit
plate
coat
specif
antigen
pathogen
interest
antibodi
serum
sampl
present
bind
fix
antigen
secondari
antibodi
conjug
enzym
alkalin
phosphatas
detect
immun
complex
colorless
substrat
pnitrophenylphosph
convert
color
product
pnitro
phenol
signal
intens
reaction
product
proport
concentr
analyt
sampl
measur
photometr
urin
test
legionella
antigen
link
oligonucleotid
probe
bind
specif
amplifi
product
monitor
fluoresc
intens
pcr
run
ie
realtim
allow
detect
quantif
accumul
product
without
reopen
reaction
tube
pcr
run
artu
sar
rg
rtpcr
kit
use
detect
novel
coron
viru
artu
sar
rg
rtpcr
kit
base
amplif
simultan
detect
specif
region
sar
corona
viru
genom
use
realtim
pcr
kit
provid
high
level
specif
sensit
reproduc
artu
sar
rg
rtpcr
kit
provid
quantit
standard
use
standard
enabl
accur
quantit
viral
load
addit
kit
contain
second
heterolog
amplif
system
identifi
possibl
pcr
inhibit
detect
intern
control
ic
differ
fluoresc
channel
analyt
pcr
detect
limit
analyt
sar
corona
viru
rtpcr
reduc
venou
blood
sampl
collect
patient
tube
ml
blood
deliv
edta
tube
perform
complet
blood
pictur
automat
cell
counter
remain
amount
blood
coagul
centrifug
rpm
min
one
part
separ
serum
use
assay
blood
chemistri
hitachi
crp
concentr
axyem
bayergermani
valu
crp
mgl
consid
abnorm
elev
second
part
serum
store
aliquot
measur
pct
time
assay
serum
pct
measur
done
use
luminesc
immunoassay
lia
specif
measur
pct
serum
use
elecy
lia
pct
coval
bound
paramagnet
particl
limit
bind
site
acridin
esterlabel
antibodi
invers
relationship
exist
concentr
label
antibodi
bound
antigen
pct
patient
sampl
trigger
chemiluminesc
reaction
result
emiss
photon
light
photo
multipli
tube
detect
photon
light
emit
convert
electr
puls
instrument
count
electr
puls
read
result
master
curv
defin
assay
result
calcul
standard
curv
ngml
detect
limit
assay
ngml
patient
divid
two
group
group
includ
patient
male
femal
bacteriolog
cultur
neg
group
includ
patient
male
femal
bacteriolog
cultur
posit
given
antibiot
therapi
accord
antibiot
sensit
test
normal
ngml
infant
h
adult
suspect
lower
respiratori
tract
infect
ngml
low
likelihood
bacteri
infect
antibiot
discourag
ngml
increas
likelihood
bacteri
infect
antibiot
encourag
suspect
sepsi
strongli
consid
initi
antibiot
unstabl
patient
ngml
low
likelihood
sepsi
ngml
increas
likelihood
sepsi
ngml
high
risk
sepsi
ngml
septic
shock
higher
pct
level
associ
wors
prognosi
antibiot
administ
repeat
procalcitonin
test
everi
day
consid
earli
antibiot
cessat
shown
fig
limit
procalcitonin
fals
posit
fals
neg
result
occur
clinic
context
guid
interpret
pct
result
fals
posit
result
situat
pct
elev
may
due
nonbacteri
caus
newborn
h
interpret
level
usual
massiv
stress
sever
trauma
surgeri
cardiac
shock
burn
treatment
agent
stimul
cytokin
antilymphocyt
globulin
alemtuzumab
granulocyt
transfus
malaria
fungal
infect
prolong
sever
cardiogen
shock
organ
perfus
abnorm
form
vascul
acut
graft
vs
host
diseas
paraneoplast
syndrom
due
medullari
thyroid
small
cell
lung
cancer
pct
level
may
rise
local
infect
parapneumon
effus
locul
infect
empyema
osteomyel
local
abscess
etc
sampl
taken
pct
measur
earli
cours
infect
patient
take
steroid
inhibit
pathway
pct
product
import
patient
chronic
lung
condit
copd
asthma
pulmonari
fibrosi
patient
characterist
reveal
signific
differ
detect
group
cultur
neg
group
group
patient
cultur
posit
group
regard
age
sex
symptom
sign
bodi
temperatur
final
diagnosi
tabl
tabl
show
signific
increas
crp
level
highli
signific
increas
pct
level
group
compar
group
initi
diagnosi
signific
differ
regard
white
blood
cell
count
blood
gase
detect
also
signific
differ
detect
regard
number
admit
patient
intens
care
unit
admiss
admit
day
group
group
patient
shown
tabl
tabl
show
number
percentag
bacteri
organ
isol
group
patient
patient
pneumonia
streptococcu
pneumonia
morexella
catarrhali
pseudomona
spp
isol
bacteria
isol
sputum
case
blood
case
case
patient
copd
pneumonia
hemophilu
influenza
staphylococcu
aureu
p
spp
isol
bacteria
isol
sputum
case
blood
case
case
pneumoia
aureu
pseudomona
spp
catarrhali
isol
patient
bronchiti
bacteria
isol
sputum
case
blood
case
one
case
blood
sputum
cultur
neg
case
acut
exacerb
asthma
tabl
demonstr
valu
pct
crp
diagnosi
lower
respiratori
tract
bacteri
infect
cutoff
valu
ngml
pct
gave
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
diagnost
effici
tabl
show
highli
signific
decreas
pct
crp
level
group
patient
antibiot
therapi
also
white
blood
cell
count
significantli
decreas
compar
pretreat
level
statist
analysi
data
done
use
spss
comput
program
version
comparison
two
parametr
quantit
variabl
done
use
student
test
chi
squar
use
compar
qualit
variabl
p
valu
consid
statist
signific
consid
insignific
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
diagnost
effici
calcul
identifi
true
gold
standard
diagnosi
respiratori
infect
often
problemat
use
blood
sputum
cultur
signific
limit
durat
time
requir
obtain
posit
cultur
issu
colon
contamin
addit
inabl
grow
certain
bacteria
standard
cultur
studi
evalu
valu
pct
rapid
sensit
marker
diagnosi
bacteri
lower
respiratori
tract
infect
need
antimicrobi
treatment
valu
prognosi
follow
therapi
also
assess
valu
procalcitonin
pct
compar
marker
infect
includ
creactiv
protein
crp
total
whiteblood
cell
count
wbc
predict
bacteri
lower
respiratori
tract
infect
current
studi
reveal
signific
differ
bacteri
cultur
neg
group
cultur
posit
group
regard
age
pct
rise
adequ
decreas
consid
possibl
treatment
failur
evalu
need
expand
antibiot
coverag
diagnost
evalu
figur
use
pct
initi
cessat
antibiot
sex
clinic
manifest
blood
gase
number
admit
patient
intens
care
unit
admiss
admit
day
group
patient
may
hinder
diagnosi
proper
therapeut
interfer
data
regard
clinic
diagnosi
show
statist
signific
differ
cultur
posit
cultur
neg
group
explain
presenc
differ
etiolog
factor
caus
respiratori
tract
infect
cultur
use
studi
detect
bacteri
infect
cultur
neg
case
infect
may
due
caus
includ
virus
copd
bronchial
asthma
exacerb
associ
number
etiolog
factor
may
infecti
non
infecti
viral
infect
import
trigger
exacerb
former
higher
percentag
latter
controversi
exist
regard
need
antimicrobi
agent
acut
exacerb
copd
find
agreement
sethi
murphi
found
quarter
patient
acut
exacerb
copd
estim
benefit
addit
antibiot
treatment
result
demonstr
pct
crp
superior
discriminatori
power
total
wbc
detect
bacteri
lower
respiratori
tract
infect
total
wbc
elev
group
statist
signific
differ
crp
acut
phase
protein
plasma
halflif
constant
almost
condit
crp
wide
use
clinic
diagnost
tool
infect
identif
current
studi
crp
good
marker
bacteri
lower
respiratori
tract
infect
level
significantli
increas
group
cultur
posit
patient
group
cultur
neg
patient
white
blood
cell
count
crp
consid
nonspecif
inflammatori
figur
use
pct
diagnosi
bacteri
infect
prognosi
sever
antibiot
therapi
role
procalcitonin
guid
diagnosi
prognosi
decis
antibiot
therapi
paramet
chang
reliabl
denot
may
enough
diagnos
bacteri
infect
studi
antibiot
therapi
pct
level
drop
group
patient
compar
pretreat
level
one
studi
et
al
evalu
pct
number
patient
communityacquir
pneumonia
cap
typic
pathogen
mostli
streptococcu
pneumonia
pct
increas
significantli
bacterem
patient
compar
patient
without
identifi
bacteri
pathogen
anoth
studi
focus
potenti
pct
differenti
patient
viral
respiratori
infect
without
bacteri
super
infect
investig
patient
confirm
influenza
pneumonia
critic
care
set
pct
differenti
patient
bacteri
superinfect
patient
viral
pneumonia
differ
studi
evalu
prognost
potenti
pct
patient
respiratori
infect
mainli
patient
cap
greatest
benefit
pct
found
patient
classifi
high
risk
pneumonia
sever
index
score
pct
ngml
exclud
mortal
highrisk
patient
subsequ
repeat
measur
pct
popul
demonstr
improv
clinic
outcom
fall
pct
level
addit
studi
found
pct
help
predict
seriou
advers
event
icu
admiss
caprel
complic
base
studi
prognost
use
pct
patient
respiratori
infect
may
summar
follow
lowrisk
patient
respiratori
infect
pct
level
ngml
identifi
patient
lower
risk
bacteri
caus
cap
thu
low
mortal
lowrisk
patient
respiratori
infect
pct
level
ngml
identifi
patient
higher
risk
bacteri
caus
cap
perhap
higher
mortal
highrisk
popul
pct
level
ngml
effect
decreas
likelihood
mortal
bacteri
caus
nonbacteri
patholog
aggress
consid
number
protocol
use
pct
measur
recommend
fig
patient
low
probabl
bacteri
infect
eg
patient
suspect
nonpneumon
respiratori
infect
singl
pct
measur
cutoff
ngml
certainli
ngml
exclud
bacteri
infect
need
initi
antibiot
therapi
fig
clinic
followup
remeasur
pct
within
h
consid
patient
antibiot
withheld
show
clinic
deterior
pct
ngml
particularli
ngml
bacteri
infect
becom
like
necessit
antibiot
therapi
patient
clinic
stabl
present
pneumonia
pct
level
ngml
strongli
suggest
bacteri
infect
antibiot
therapi
initi
pct
reassess
everi
day
antibiot
may
discontinu
patient
show
clinic
recoveri
pct
decreas
ngml
least
peak
level
highli
elev
pct
level
situat
make
bacterem
diseas
like
suggest
infect
may
sever
expect
base
clinic
sign
symptom
patient
suspect
pneumonia
base
presenc
radiolog
infiltr
persist
h
pct
level
ngml
even
ngml
ngml
argu
typic
bacteri
infect
physician
consid
unusu
pneumonia
pulmonari
embol
acut
heart
failur
bronchiol
obliteran
organ
pneumonia
pneumocysti
jiroveci
pneumonia
viral
pneumonia
particularli
flu
season
antibiot
withheld
initi
pct
recheck
h
pct
level
ngml
bacteri
infect
still
highli
suspect
base
clinic
present
microbiolog
result
antibiot
therapi
consid
pct
remain
low
followup
earli
discontinu
antibiot
consid
well
aggress
diagnost
workup
caus
highrisk
patient
icu
sever
respiratori
infect
fig
empir
antibiot
therapi
initi
still
initi
pct
level
ngml
argu
typic
bacteri
infect
diagnos
consid
includ
viral
caus
repeat
pct
level
h
highrisk
patient
may
import
miss
evolut
inflammatori
cascad
similar
strategi
use
serial
troponin
monitor
cardiac
ischemia
pct
level
decreas
remain
high
treatment
failur
consid
reassess
patient
recommend
pct
standalon
test
replac
clinic
evalu
patient
pct
need
interpret
consider
clinic
set
